Citations

Clear

186 citation(s) found for "Frantz, R".

Risk Prediction Models Are Associated with Patient Centered Outcomes in PAH: The Pulmonary Hypertension Association Registry
Feldman, Jeremy P., Sager, J.S., Shlobin, Oksana A. , McConnell, J.W. , Klinger, James R. , Zamanian, Roham T. , Robinson, Jeffrey C. , Elwing, Jean , Badesch, David B., Ryan, John , Mazimba, Sula , Grinnan, D. , Chakinala, Murali M. , Min, Jeff , Lammi, Matthew R. , Frantz, Robert P. , Ventetuolo, Corey E. , Thenappan, Thenappan , Simon, Marc A. , Horn, Evelyn M. , Al‐Naamani, Nadine

Mayo Clinic

B27. UP-TO-DATE PAH ASSESSMENT AND MANAGEMENT | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2912-A2912

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2912 Get It

Health Disparities and Treatment Patterns in Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension: An Analysis of the Pulmonary Hypertension Association Registry
Bartolome, Sonja, Feldman, Jeremy P., Sager, Jeffrey S., Presberg, Kenneth W., Mathai, S.C. , Klinger, James R. , Eggert, Michael, Robinson, Jeffrey C. , Fineman, Jeff, Marco, Teresa De , Elwing, Jean , Badesch, David B., Bull, Todd M., Cadaret, Linda , Ramani, Gautam , Ford, H. James , Mazimba, Sula , Runo, James , Chakinala, Murali M. , Ryan, John , Grinnan, D. , Krowka, Michael J. , DuBrock, Hilary M. , Burger, Charles D. , Rosenzweig, Erika B. , Lammi, Matthew R. , Thenappan, Thenappan , Al‐Naamani, Nadine , Simon, Marc A. , Horn, Evelyn M. , Frantz, Robert P.

Mayo Clinic

B27. UP-TO-DATE PAH ASSESSMENT AND MANAGEMENT | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2906-A2906

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2906 Get It

Quality of Life as Assessed by the SYMPACT Questionnaire in Patients with Chronic Thromboembolic Pulmonary Hypertension
Koubek, Richard , Durst, Louise A., Head, Denise , Sands, Terry, Krowka, Michael J. , Kushwaha, Sudhir S. , McCully, Robert B. , Murphy, Joseph G. , Head, D., Cajigas, Héctor , Kane, Garvan C. , DuBrock, Hilary M. , Frantz, Robert P.

Mayo Clinic

A54. WHAT'S NEW IN CTEPH?: CLINICAL STUDIES | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2046-A2046

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2046 Get It

A Platform to Combine Clinical, Prescription, and Dispensing Data to Better Inform Idiopathic Pulmonary Fibrosis Care; The Trio Registry
Nathan, S.D., Chakinala, Murali M. , Frost, Adaani , Lancaster, Lisa , Milligan, K. R., Frantz, Robert P. , Milligan, K., Milligan, Scott , Oudiz, Ronald J. , Farber, Harrison W.

Mayo Clinic

A37. ILD THERAPY I | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A1519-A1519

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1519 Get It

Biceps Tenodesis for Superior Labrum Anterior-Posterior Tear in the Overhead Athlete: A Systematic Review
Frantz, Travis L. , Shacklett, Andrew G., Martin, Adam S. , Jones, Grant L. , Neviaser, Andrew S. , Cvetanovich, Gregory L. , Barlow, Jonathan D.

Mayo Clinic

The American Journal of Sports Medicine | June 24, 2020 | Volume: 49 | Issue: 2 | Pages: 522-528

10.1177/0363546520921177 | PMID 32579853 Get It

Background: Superior labrum anterior-posterior (SLAP) lesion is a common shoulder injury, particularly in overhead athletes. While surgical management has traditionally consisted of SLAP repair, high rates of revision and complications have led to alternative techniques, such as biceps tenodesis (BT). While BT is commonly reserved for older nonoverhead athletes, indications for its use have expanded in recent years. Purpose: To determine functional outcomes and return-to-sport rates among overhead athletes after BT for SLAP tear. Study Design: Systematic review. Methods: A systematic review was performed for any articles published before July 2019. The search phrase “labral tear” was used to capture maximum results, followed by keyword inclusion of “SLAP tear” and “biceps tenodesis.” Inclusion criteria included outcome studies of BT for isolated SLAP tear in athletes participating in any overhead sports, not limited to throwing alone. Abstracts and manuscripts were independently reviewed to determine eligibility. When clearly delineated, outcome variables from multiple studies were combined. Results: After full review, 8 articles met inclusion criteria (99 athletes; mean age, 19.8-47 years), with baseball and softball players the most common among them (n = 62). Type II SLAP tear was the most common diagnosis, and 0% to 44% of athletes had a failed previous SLAP repair before undergoing BT. Only 1 study included patients with concomitant rotator cuff repair. Open subpectoral BT was most commonly used, and complication rates ranged from 0% to 14%, with wound erythema, traumatic biceps tendon rupture, brachial plexus neurapraxia, and adhesive capsulitis being reported. Combined reported postoperative functional scores were as follows: American Shoulder and Elbow Surgeons, 81.7 to 97; 12-Item Short Form Health Survey physical, 50 to 54; visual analog scale for pain, 0.8-1.5; Kerlan Jobe Orthopaedic Clinic, 66 to 79; and satisfaction, 80% to 87%. The overall return-to-sports rate for overhead athletes was 70% (60 of 86). For studies that clearly delineated outcomes based on level of play/athlete, the combined return-to-sports rate was 69% (11 of 16) for recreational overhead athletes, 80% (4 of 5) for competitive/collegiate athletes, and 60% (18 of 30) for professionals. Conclusion: BT in the overhead athlete offers encouraging functional outcomes and return-to-sports rates, particularly in the recreational athlete. It can be successfully performed as an index operation rather than SLAP repair, as well as in a younger patient population. Careful consideration should be given to elite overhead athletes, particularly pitchers, who tend to experience poorer outcomes.
Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one‐day versus seven‐day symptom reporting
Chin, Kelly , Zhao, Carol, Flynn, Megan , Badesch, David B., Chin, Kelly M , Frantz, Robert P.

Mayo Clinic

Pulmonary Circulation | April 17, 2020 | Volume: 10 | Issue: 2 | Pages: 1-9

10.1177/2045894020923957 | PMID 32489644 Get It

Patient‐reported outcomes are important measures to include in pulmonary arterial hypertension clinical trials but are not widely utilized in clinical practice. Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire (PAH‐SYMPACT) is the only pulmonary arterial hypertension‐specific patient‐reported outcomes instrument developed and validated in accordance with the US Food and Drug Administration guidance on patient‐reported outcomes development. The PAH‐SYMPACT tool measures pulmonary arterial hypertension‐related symptoms and impact of pulmonary arterial hypertension on daily life. Symptoms are reported each day for seven consecutive days, and the impact of pulmonary arterial hypertension over one week is recalled and reported on day 7; however, daily symptom reporting may overburden patients and healthcare resources, limiting the practicality of PAH‐SYMPACT outside of clinical trials. To determine the practicability of an abridged version of PAH‐SYMPACT for which all reporting is completed on one day, symptom data from the SYMPHONY trial (NCT01841762; PAH‐SYMPACT validation study) were retrospectively analyzed to assess whether symptoms reported on each day correlated with the weekly average and whether one‐day symptom scores were sensitive to disease severity. Correlation coefficients comparing the weekly average and individual day symptom scores were mostly high or very high regardless of the day they were measured. Findings were similar when using either Spearman's rank correlation or weighted kappa method. One‐day symptom scores differentiated well between World Health Organization functional classes II and III/IV pulmonary arterial hypertension and were sensitive to change in disease severity as measured by the Patient Global Assessment of Disease Severity. These data suggest that the one‐day PAH‐SYMPACT is feasible and appropriate for routine implementation in clinical practice.
Ultrasound-Guided Cooled Radiofrequency Ablation of the Genicular Nerves: A Technique Paper
Lash, Dustin, Frantz, Earl, Hurdle, Mark FB

Mayo Clinic

Pain Management | March 4, 2020 | Volume: 10 | Issue: 3 | Pages: 147-157

10.2217/pmt-2019-0067 | PMID 32129148 Get It

Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease
Tang, W.H. Wilson , Wilcox, Jennifer , Jacob, Miriam , Frantz, Robert P. , Hill, Nicholas S. , Singh, Harsimran , Xiao, Lei , Rischard, Franz , Group, the PVDOMICS Study, Tang, W H Wilson , Frantz, Robert P , Rischard, Franz P , Wilcox, Jennifer D , Rosenzweig, Erika B. , Borlaug, Barry A. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Systrom, David M , Tedford, Ryan J. , Vanderpool, Rebecca , Waxman, Aaron B. , Leopold, Jane A. , Group, the PVDOMICS Study

Mayo Clinic

Circulation: Heart Failure | February 24, 2020 | Volume: 13 | Issue: 3 | Pages: No page available

10.1161/circheartfailure.119.006363 | PMID 32088984 Get It

Background: Invasive hemodynamic evaluation through right heart catheterization plays an essential role in the diagnosis, categorization, and risk stratification of patients with pulmonary hypertension. Methods: Subjects enrolled in the PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) program undergo an extensive invasive hemodynamic evaluation that includes repeated measurements at rest and during several provocative physiological challenges. It is a National Institutes of Health/National Heart, Lung, and Blood Institute initiative to reclassify pulmonary hypertension groups based on clustered phenotypic and phenomic characteristics. At a subset of centers, participants also undergo an invasive cardiopulmonary exercise test to assess changes in hemodynamics and gas exchange during exercise. Conclusions: When coupled with other physiological testing and blood -omic analyses involved in the PVDOMICS study, the comprehensive right heart catheterization protocol described here holds promise to clarify the diagnosis and clustering of pulmonary hypertension patients into cohorts beyond the traditional 5 World Symposium on Pulmonary Hypertension groups. This article will describe the methods applied for invasive hemodynamic characterization in the PVDOMICS program. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02980887.
Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous‐Flow Left Ventricular Assist Devices
Alnsasra, Hilmi , Daly, Richard C. , Schettle, Sarah , Briasoulis, Αlexandros , Taher, Riad, Stulak, John M., Behfar, Atta , Pereira, Naveen L. , Frantz, Robert P. , Edwards, Brooks S., Clavell, Alfredo L. , Kushwaha, Sudhir S. , Asleh, Rabea , Schettle, Sarah D., Dunlay, Shannon M. , Behfar, Atta , Briasoulis, Alexandros , Frantz, Robert P

Mayo Clinic

Journal of the American Heart Association | November 8, 2019 | Volume: 8 | Issue: 22 | Pages: No page available

10.1161/jaha.119.013108 | PMID 31701791 Get It

Background The presence of a durable left ventricular assist device ( LVAD ) is associated with increased risk of vasoplegia in the early postoperative period following heart transplantation ( HT ). However, preoperative predictors of vasoplegia and its impact on survival after HT are unknown. We sought to examine predictors and outcomes of patients who develop vasoplegia after HT following bridging therapy with an LVAD . Methods and Results We identified 94 patients who underwent HT after bridging with continuous‐flow LVAD from 2008 to 2018 at a single institution. Vasoplegia was defined as persistent low vascular resistance requiring ≥2 intravenous vasopressors within 48 hours after HT for >24 hours to maintain mean arterial pressure >70 mm Hg. Overall, 44 patients (46.8%) developed vasoplegia after HT . Patients with and without vasoplegia had similar preoperative LVAD , echocardiographic, and hemodynamic parameters. Patients with vasoplegia were significantly older; had longer LVAD support, higher preoperative creatinine, longer cardiopulmonary bypass time, and higher Charlson comorbidity index; and more often underwent combined organ transplantation. In a multivariate logistic regression model, older age (odds ratio: 1.08 per year; P =0.010), longer LVAD support (odds ratio: 1.06 per month; P =0.007), higher creatinine (odds ratio: 3.9 per 1 mg/dL; P =0.039), and longer cardiopulmonary bypass time (odds ratio: 1.83 per hour; P =0.044) were independent predictors of vasoplegia. After mean follow‐up of 4.0 years after HT , vasoplegia was associated with increased risk of all‐cause mortality (hazard ratio: 5.20; 95% CI, 1.71–19.28; P =0.003). Conclusions Older age, longer LVAD support, impaired renal function, and prolonged intraoperative CPB time are independent predictors of vasoplegia in patients undergoing HT after LVAD bridging. Vasoplegia is associated with worse prognosis; therefore, detailed assessment of these predictors can be clinically important.
Sequential Heart and Autologous Stem Cell Transplantation for AL Amyloidosis.
Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Kyle, Robert A. , Edwards, Brooks S., Rodeheffer, Richard J. , Robert, Frantz P., Kushwaha, Sudhir S. , Clavell, Alfedo L., Sundt, Thoralf M. , Daly, Richard C. , McGregor, Christopher G.A. , Gastineau, Dennis A. , Dispenzieri, Angela , Rajkumar, S. Vincent , Dearani, Joseph A. , Gertz, Morie A.

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 3092-3092

10.1182/blood.v108.11.3092.3092 Get It

Abstract Background: Patients with AL and congestive heart failure have a median survival of less than one year. Methods: Between 1994 and 2005, 11 patients underwent sequential heart transplant followed by autologous peripheral blood stem cell transplant (SCT) for treatment of AL. Patients had heart dominant AL with minimal/no other organ impairment and no evidence of multiple myeloma. Results: Patients ranged in age from 35 to 63 years (median 54). All had biopsy proven amyloidosis and monoclonal protein detectable in serum (73%) or urine (100%). Free light chain assay was available prior to SCT in 6 and was abnormal in all. All patients presented with NYHA Class III or IV heart failure. All but two patients had no other organ involved at the time of heart transplant. One patient had his heart transplant at another facility and had renal involvement at the time of heart transplant. One patient had peripheral nerve involvement documented prior to heart transplant. Five patients had progression of amyloid to involve other organs by the time of SCT. These included: renal (6), peripheral nerve (2), macroglossia (3), gastrointestinal (2). The median time from diagnosis to heart transplant was 3 months (range 1 to 5). The median time from heart transplant to SCT was 8 months, (range 3 to 24). Conditioning chemotherapy consisted of melphalan 200 mg /m2 (6 patients) or melphalan 140 mg/m2 (5 patients). Two patients died of complications before day +100, (TRM of 18%). Hematologic remissions were seen in 8 and organ responses in 3. Five were unable to be evaluated for organ response due to the heart transplant. Three died from progressive amyloidosis at 66, 56.7, and 55 months following SCT. The median survival is 56.7 months from SCT. Six are alive with a median follow-up of 24 months, range 9 to 90 months. Among the 6 surviving patients, one patient relapsed and one patient has failed to improve, but 4 patients are in continued remission. One patient developed secondary myelodysplastic syndrome. Conclusions: Heart transplant followed by SCT is feasible and offers durable remissions for carefully selected patients with cardiac AL. Figure Figure